ABSTRACT
Objectives: Osteoarthritis (OA) is the most common joint disease in the world, becoming more prevalent with increasing age, and causes a significant burden on individuals and society. So far, several factors have been identified in association with OA of the knee joint. Age is the most crucial uncontrollable risk factor for OA. There are conflicting results regarding the relationship between patellofemoral joint orientation and OA. This study aims to elucidate the relationship between patellofemoral joint alignment and OA evidence. Material and methods: A total of 277 MRIs performed at Imam Reza Hospital during the first half of 2017 were included. Patients were divided into two groups, under 50 years old and over 50 years old. Femoral sulcus angle (SA) and depth (SD), lateral patellar displacement (LPD), tibial tubercle-trochlear groove (TTTG), lateral patellofemoral angle (LPFA), and Insall-Salvati index were measured in axial and sagittal images. The morphology of the patellofemoral articular cartilage was evaluated and the grade of joint damage was determined. P-value < 0.05 was considered as significant. Results: Significant correlations between SA (p-value = 0.01), SD (p-value < 0.001), Insall-Salvati index (p-value < 0.001), LPD (p-value = 0.02) values and OA in patients less than 50 years old were observed. A weak correlation was observed between SD and Insall-Salvati index values with increasing grade of articular cartilage damage (r = 0.21 and r = 0.21, respectively). Conclusions: Patellofemoral joint asymmetry in the younger people was significantly associated with joint cartilage damage and premature patellofemoral joint OA. Joint misalignment by stressing the articular cartilage causes joint cartilage changes that may be congenital or due to bone injuries such as trauma and surgery.
ABSTRACT
The novel coronavirus, SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread worldwide. More than 272 million cases of infection have been identified. COVID-19 has affected 223 countries and territories across the world. The principal target of the SARS-CoV-2 infection is the lower respiratory tract. Series of moderate to non-specific severe clinical signs and symptoms appear two to fourteen days after exposure to SARS-CoV-2 in patients with COVID-19 disease, including cough, breath deficiency, and at least two of these symptoms: headache, fever, chills, repeated rigor, myalgia, oropharyngitis, anosmia, and ageusia. No therapeutic agents have been validated to have substantial efficacy in the clinical care of COVID-19 patients in large-scale trials, despite worsening infected rates of COVID-19. Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortality. The mechanism by which famotidine could improve the outcomes of COVID-19 is currently unknown. A more recent postulated mechanism is that the effect of famotidine is mediated by histamine-2 receptor antagonism or inverse agonism, inferring that the SARS-CoV-2, resulting in COVID-19 infection, at least partially leads to the abnormal release of histamine and perhaps dysfunction of mast cells.
